Adaptations of the human placenta to hypoxia: opportunities for interventions in fetal growth restriction
BACKGROUND The placenta is the functional interface between the mother and the fetus
during pregnancy, and a critical determinant of fetal growth and life-long health. In the first …
during pregnancy, and a critical determinant of fetal growth and life-long health. In the first …
16th international congress on antiphospholipid antibodies task force report on antiphospholipid syndrome treatment trends
Antiphospholipid syndrome (APS), an acquired autoimmune thrombophilia, is characterised
by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid …
by thrombosis and/or pregnancy morbidity in association with persistent antiphospholipid …
[HTML][HTML] FIGO (international Federation of Gynecology and obstetrics) initiative on fetal growth: best practice advice for screening, diagnosis, and management of fetal …
Fetal growth restriction (FGR) is defined as the failure of the fetus to meet its growth potential
due to a pathological factor, most commonly placental dysfunction. Worldwide, FGR is a …
due to a pathological factor, most commonly placental dysfunction. Worldwide, FGR is a …
Pravastatin versus placebo in pregnancies at high risk of term preeclampsia
M Döbert, AN Varouxaki, AC Mu, A Syngelaki… - Circulation, 2021 - Am Heart Assoc
Background: Effective screening for term preeclampsia is provided by a combination of
maternal factors with measurements of mean arterial pressure, serum placental growth …
maternal factors with measurements of mean arterial pressure, serum placental growth …
Prevention of preeclampsia
M Ma'ayeh, MM Costantine - Seminars in Fetal and Neonatal Medicine, 2020 - Elsevier
Preeclampsia is an obstetric disorder that affects 3–8% of pregnant women and remains a
leading cause of short-and long-term neonatal and maternal morbidity and mortality …
leading cause of short-and long-term neonatal and maternal morbidity and mortality …
Pravastatin, proton-pump inhibitors, metformin, micronutrients, and biologics: new horizons for the prevention or treatment of preeclampsia
There has been increasing research momentum to identify new therapeutic agents for the
prevention or treatment of preeclampsia, drugs that can affect the underlying disease …
prevention or treatment of preeclampsia, drugs that can affect the underlying disease …
A randomized pilot clinical trial of pravastatin versus placebo in pregnant patients at high risk of preeclampsia
Background Preeclampsia remains a major cause of maternal and neonatal morbidity and
mortality. Biologic plausibility, compelling preliminary data, and a pilot clinical trial support …
mortality. Biologic plausibility, compelling preliminary data, and a pilot clinical trial support …
[HTML][HTML] Preeclampsia: linking placental ischemia with maternal endothelial and vascular dysfunction
Preeclampsia (PE), a hypertensive disorder, occurs in 3% to 8% of pregnancies in the
United States and affects over 200,000 women and newborns per year. The United States …
United States and affects over 200,000 women and newborns per year. The United States …
The role of statins in the prevention of preeclampsia
Preeclampsia is a common hypertensive disorder of pregnancy associated with
considerable neonatal and maternal morbidities and mortalities. However, the exact cause …
considerable neonatal and maternal morbidities and mortalities. However, the exact cause …
Animal models of preeclampsia: causes, consequences, and interventions
Preeclampsia is a common pregnancy complication, affecting 2% to 8% of pregnancies
worldwide, and is an important cause of both maternal and fetal morbidity and mortality …
worldwide, and is an important cause of both maternal and fetal morbidity and mortality …